Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model
- 16 April 2004
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 22 (13-14), 1782-1790
- https://doi.org/10.1016/j.vaccine.2004.01.037
Abstract
No abstract availableThis publication has 42 references indexed in Scilit:
- Rate, Causes, and Clinical Implications of Presenting with Low CD4+ Cell Counts in the Era of Highly Active Antiretroviral TherapyAIDS Research and Human Retroviruses, 2003
- ImiquimodDermatologic Clinics, 2003
- The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-γ–producing cellsJournal of Allergy and Clinical Immunology, 2003
- NEXT GENERATION DNA VACCINES FOR HIV-1Journal of Liposome Research, 2002
- Combined Administration of Plasmids Encoding IL-4 and IL-10 Prevents the Development of Autoimmune Diabetes in Nonobese Diabetic MiceMolecular Therapy, 2001
- Ongoing trials of immune-based therapies for HIV infection in adultsExpert Opinion on Biological Therapy, 2001
- Interleukin-1 and Interleukin-1 Fragments as Vaccine AdjuvantsMethods, 1999
- Safety and immunogenicity of HIV-1 DNA constructs in chimpanzeesVaccine, 1998
- Safety and immunogenicity of intramuscular and intravaginal delivery of HIV‐1 DNA constructs to infant chimpanzeesJournal of Medical Primatology, 1997
- Immunoadjuvants and analogs of immunomodulatory bacterial structuresCurrent Opinion in Immunology, 1990